Validation of platelet expression of FC?riia as a precision tool
Ended Project Grant Awarded Last action
- Award ID
- R44HL166003
- Recipient
-
Prolocor Inc. UEI CSVAGA1DWEN5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,352,388
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- Vermont, USA
Award details come from USAspending.gov.
Description
- Abstract
- The american heart association estimates that, in 2022, about 720,000 americans will have a first coronary event and 335,000 will have a recurrent event, of which, approximately 87% are ischemic (thrombotic). Anti- thrombotic therapy reduces the risk of recurrent ischemic events at the cost of a greater incidence of bleeding complications. Patients at low thrombotic/ischemic risk should benefit from shortened treatment whereas patients at high thrombotic/ischemic risk should derive greater absolute benefit from longer term treatment with more powerful antiplatelet therapy. Currently available tools such as clinical risk scores and platelet function testing are inadequate to effectively individualize cardiovascular care, and effective precision medicine strategies to enable clinicians to target patients with high residual risk are lacking. Platelet function tests effectively identify patients at risk but failed when used in trials designed to guide treatment. Key weaknesses of platelet function tests include that they demonstrate substantial intra-individual variability, are influenced by both assay conditions as well as the treatment of the patient, and that they measure platelet reactivity in response to a select agonist or group of agonists. To address this GAP in patient care, prolocor identified a biomarker, fcriia, on the surface of platelets. When platelets activate, fcriia amplifies platelet activation. Thus, increased platelet fcriia increases platelet reactivity and leverages the prognostic implications of platelet function tests. Compared to currently available platelet function tests, expression of fcriia shows less intra-individual variability, is substantially less sensitive to perturbations related to assay conditions, and predicts increased platelet reactivity in response to a variety of agonists. In a preliminary study of 197 patients, COX regression analysis demonstrated that platelet expression of fcriia was the sole covariate (hazard ratio 3.9, p=0.035) associated with an increased risk of heart attack, stroke, and death when age, diabetes, and prior revascularization were included as covariates. Thus, quantifying platelet fcriia expression is a novel method to identify cardiovascular risk and should serve as a powerful precision medicine tool. Prolocor has since refined the assay by developing antibodies that bind to fcyriia on the surface of platelets that have been fixed with formaldehyde. Initial analytic testing has demonstrated excellent precision (coefficient of variation of repeated tests
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $50,000 | |
| Amendment | $693,288 | |
| Amendment | $693,288 | |
| Amendment | $687,938 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $613,937 | |
| Original award | $613,937 |
Quick answers
Who received award R44HL166003?
R44HL166003 was awarded to Prolocor Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 11, 2022.
How much is award R44HL166003 worth?
$3,352,388 has been obligated on R44HL166003.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award